ArticleMultiple sclerosis journal - experimental, translational and clinical
No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.
Eva Havrdová et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
36 papers cite it
trialcites it